Major Assets

Major Marketed Programs

Of the seven currently marketed, partnered programs, some are more prominent in driving current and/or future revenue growth. These programs include:

-Promacta
-Kyprolis
-Duavee

The Big Six

We have also identified six development stage drugs from our portfolio of over 120 partnered programs that stand out as having the potential to add significantly to Ligand’s top and bottom lines. The programs contained in this group have been identified for a variety of reasons including;

- Significant market size or therapeutic area addressed
- Important upcoming milestone events over the next 6 to 24 months
- Impactful potential royalties or other deal economics

We call these promising programs The Big Six.

Partner Program (Therapy Area) Stage Royalty Rate Potential Launch
CE-Melphalan
(Oncology)
NDA20%2015
Delafloxacin IV
(Infection)
Phase 3Undisclosed2016
SAGE-547
(Neurology)
Phase 2Undisclosed2017
Sparsentan
(FSGS - Kidney Disease)
Phase 29%2017
MK-8931
(Alzheimer's Disease)
Phase 3Undisclosed2018
IRAK-4
(Oncology)
Preclinical6.0-9.5%2019